245 related articles for article (PubMed ID: 26296048)
1. Fatal intracerebral bleeding under rivaroxaban.
Stöllberger C; Bastovansky A; Finsterer J
Int J Cardiol; 2015 Dec; 201():110-2. PubMed ID: 26296048
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
[TBL] [Abstract][Full Text] [Related]
3. Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.
Engelberger RP; Noll G; Schmidt D; Alatri A; Frei B; Kaiser WE; Kucher N
Eur J Intern Med; 2015 Sep; 26(7):508-14. PubMed ID: 25935131
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
[TBL] [Abstract][Full Text] [Related]
5. Favorable outcome of rivaroxaban-associated intracerebral hemorrhage reversed by 4-factor prothrombin complex concentrate: impact on thrombin generation.
Kauffmann S; Chabanne R; Coste A; Longeras F; Sinegre T; Schmidt J; Samama CM; Constantin JM; Lebreton A
A A Case Rep; 2015 Jun; 4(11):151-4. PubMed ID: 26035221
[TBL] [Abstract][Full Text] [Related]
6. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
7. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
Piccini JP; Garg J; Patel MR; Lokhnygina Y; Goodman SG; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Nessel CC; Mahaffey KW; Singer DE; Califf RM; Fox KA;
Eur Heart J; 2014 Jul; 35(28):1873-80. PubMed ID: 24658769
[TBL] [Abstract][Full Text] [Related]
8. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
9. Rıvaroxaban-induced severe diffuse ıntracerebral hemorrhage.
Çalışkan F; Akdemir HU; Nurata H; Akdemir N; Başara G; Yavuz Y
Am J Emerg Med; 2015 Mar; 33(3):475.e1-5. PubMed ID: 25218622
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital.
Tellor KB; Patel S; Armbruster AL; Daly MW
J Clin Pharm Ther; 2015 Aug; 40(4):447-51. PubMed ID: 26010016
[TBL] [Abstract][Full Text] [Related]
11. Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS Trial.
Mikulík R; Eckstein J; Pearce LA; Mundl H; Rudilosso S; Olavarría VV; Shoamanesh A; Chamorro Á; Martí-Fàbregas J; Veltkamp R; Öztürk Ş; Tatlisumak T; Peacock WF; Berkowitz SD; Connolly SJ; Hart RG
Stroke; 2020 Jul; 51(7):2139-2147. PubMed ID: 32517582
[TBL] [Abstract][Full Text] [Related]
12. Association of rivaroxaban anticoagulation and spontaneous vitreous hemorrhage.
Jun JH; Hwang JC
JAMA Ophthalmol; 2015 Oct; 133(10):1184-6. PubMed ID: 26111247
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous, Life-Threatening Hemorrhagic Cardiac Tamponade Secondary to Rivaroxaban.
Kham NM; Song M
Am J Ther; 2016; 23(4):e1128-31. PubMed ID: 26035030
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
[TBL] [Abstract][Full Text] [Related]
15. [Repeated Cerebellar Hemorrhage Related to Rivaroxaban and Apixaban: A Case Report].
Yokoi M; Toyama Y; Tsurusaki Y; Nakamura A; Mima Y; Kuwashiro T; Wakugawa Y; Yasaka M; Okada Y
Brain Nerve; 2016 May; 68(5):573-7. PubMed ID: 27156511
[TBL] [Abstract][Full Text] [Related]
16. Retrospective Evaluation of Postoperative Bleeding Events in Patients Receiving Rivaroxaban After Undergoing Total Hip and Total Knee Arthroplasty: Comparison with Clinical Trial Data.
Wood RC; Stewart DW; Slusher L; El-Bazouni H; Cluck D; Freshour J; Odle B
Pharmacotherapy; 2015 Jul; 35(7):663-9. PubMed ID: 26095331
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
Gorzelak-Pabiś P; Duraj I; Szlagowska L; Ciastkowska A; Broncel M
Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985
[TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
Spencer RJ; Amerena JV
Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
[TBL] [Abstract][Full Text] [Related]
19. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.
Cappato R; Ezekowitz MD; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca M; Vardas PE; Kirchhof P; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M; Hohnloser SH;
Eur Heart J; 2014 Dec; 35(47):3346-55. PubMed ID: 25182247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
